• Use of PMI's own proprietary drug delivery systems for the controlled release of antimicrobial agents and antibiotics;
• Use of a proprietary technology to chemically activate hydrophobic substrates for rendering them hydrophilic and imparting microbicidal activities;
• Development of PMI proprietary radiochemical sterilization technology for use in medical devices;
• Development of a patented absorbable tissue adhesive and wound closure devices for use in surgical and minimally invasive procedures;
• Development of a patented absorbable liquid gel-former for pharmaceutical and biomedical applications;
• Development of novel self-fiber-reinforced composites;
• Development of surface conducting polymers for use in antistatic biomedical fabrics, electromagnetic barriers, and conducting biomedical devices;
• Development of novel fibrous constructs for tissue repair and in situ tissue engineering;
• Development of novel, non-hormonal intravaginal contraceptive ring system;
• Development of novel absorbable bicomponent meshes for hernia repair;
• Development of a novel absorbable, composite, ureteral stent;
• Development of novel antibacterial and antifungal intravaginal rings;
• Development of 2- and 3-component analgesic tablets for combination therapy; and,
• Development of novel hydroswellable absorbable sutures.

In early 1996, PMI established the Validation & Analytical Center as a new division dedicated, in part, to contract GLP and non-GLP activities.
In 2003, PMI moved into its own new R&D laboratory at the Clemson Research Park. Due to increased company activities and advances in technology partnerships, PMI expanded to occupy its second new facility at the Clemson Research Park for advanced development and processing in the state-of-the-art bioengineering center in mid-2005. Having the PMI facilities within close proximity to Clemson University and The Greenville Hospital System, with their most pertinent research and clinical facilities and highly qualified faculty and medical staff, allows PMI to (a) subcontract certain project segments, thus reducing the need for high-cost capital equipment; (b) solicit joint federal grants and contracts to help create new business opportunities; (c) have a strong technical consultation arrangement with faculty; (d) have access to academic seminars, library, and animal research facilities; and (e) pursue collaborative research in material science and engineering with emphasis on bioengineering.  In concert with its on-going collaboration with Clemson University, PMI has forged a unique joint education/research program which allows full-time PMI employees to enroll in the bioengineering graduate program toward receiving M.S. and/or Ph.D. Degrees in Bioengineering.

For the past several years, PMI has directed its R&D efforts toward establishing partnerships with manufacturing/marketing companies based on its proprietary materials and technologies. These included absorbable controlled drug delivery for dental and vascular applications, vascular graft sealants, vascular sealants, absorbable microfilament and multifilament sutures and allied devices, novel forms of knitted meshes for tissue repair, and absorbable tissue adhesives.
PMI operations are overseen by an advisory board with members having strong technical, marketing, and financial backgrounds. The daily operation is directed by Dr. Shalaby W. Shalaby who has had a diverse academic background (undergraduate in chemistry, botany, and pharmacy, M.S. in textiles, Ph.D. in chemistry and polymer science) and over 35 years of extensive industrial and academic experience in polymers and several health care technology areas, with specific expertise in advanced materials research and development, molecular and engineering design of biomaterials, patenting, licensing, and acquiring new technologies. His academic appointments include the post of Professor of Bioengineering at Clemson University as well as adjunct appointments at Rutgers University and the University of Connecticut. In Industry, he served as Senior Director/Corporate Scientist at United States Surgical Corporation, and prior to this, Manager of the Johnson & Johnson Polymer Technology Center.  At Poly-Med, he received the award for Biomaterial Innovation from the Society For Bioengineering in 2005.

PMI management is supported by a 5-member Advisory Board consisting of a general counsel (M.S., J.D.) responsible for executing intellectual property-related matters and intercompany agreements, a practicing surgeon (M.D., Ph.D.) who provides guidance in the development of surgical products, a practicing physician (M.D.) who provides general guidance in the development of various healthcare products, CEO (M.B.A.) of a company  specializing in technology-business integration who oversees PMI operations and strategic planning, and an M.B.A. holder with extensive experience in sales who provides guidance in marketing and sales strategy.